RU2014116566A - MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION - Google Patents
MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION Download PDFInfo
- Publication number
- RU2014116566A RU2014116566A RU2014116566/15A RU2014116566A RU2014116566A RU 2014116566 A RU2014116566 A RU 2014116566A RU 2014116566/15 A RU2014116566/15 A RU 2014116566/15A RU 2014116566 A RU2014116566 A RU 2014116566A RU 2014116566 A RU2014116566 A RU 2014116566A
- Authority
- RU
- Russia
- Prior art keywords
- dehydroepiandrosterone
- microns
- content
- amount
- agent
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Средство на основе дегидроэпиандростерона, характеризующееся тем, что в состав средства входят микронизированный порошок дегидроэпиандростерона с размерами частиц от 1 до 5 мкм либо его микроэмульсия с размером частиц от 2 до 5 мкм и натуральный биосовместимый наноструктурированный гель хитозана с содержанием дегидроэпиандростерона от 5 до 10 мг в 1 мл.2. Способ применения средства по п. 1 для влагалищного введения менопаузальным женщинам, страдающим вульвовагинальной атрофией, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием применяемой минимальной физиологической дозы дегидроэпиандростерона не более 5-10 мг.3. Способ применения средства по п. 1 для чрескожного введения лицам пожилого возраста обоего пола для нормализации стероидного метаболизма и компенсации дефицита дегидроэпиандростерона и тестостерона, отличающийся тем, что количество ежедневно наносимого средства составляет не более 1 мл с содержанием дегидроэпиандростерона не более 5-10 мг.1. The product is based on dehydroepiandrosterone, characterized in that the composition of the product includes micronized dehydroepiandrosterone powder with particle sizes from 1 to 5 microns or its microemulsion with a particle size of 2 to 5 microns and a natural biocompatible nanostructured chitosan gel with a dehydroepiandrosterone content of from 5 to 10 mg in 1 ml. 2. The method of using the agent according to claim 1 for vaginal administration to menopausal women suffering from vulvovaginal atrophy, characterized in that the amount of daily applied agent is not more than 1 ml with a minimum physiological dose of dehydroepiandrosterone of not more than 5-10 mg. 3. The method of using the agent according to claim 1 for transdermal administration of the elderly to both sexes to normalize steroid metabolism and compensate for the deficiency of dehydroepiandrosterone and testosterone, characterized in that the amount of daily applied agent is not more than 1 ml with a dehydroepiandrosterone content of not more than 5-10 mg.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014116566/15A RU2592370C9 (en) | 2014-04-24 | 2014-04-24 | Agent based on dehydroepiandrosterone, method for use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014116566/15A RU2592370C9 (en) | 2014-04-24 | 2014-04-24 | Agent based on dehydroepiandrosterone, method for use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2014116566A true RU2014116566A (en) | 2015-10-27 |
RU2592370C2 RU2592370C2 (en) | 2016-07-20 |
RU2592370C9 RU2592370C9 (en) | 2016-08-27 |
Family
ID=54362699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014116566/15A RU2592370C9 (en) | 2014-04-24 | 2014-04-24 | Agent based on dehydroepiandrosterone, method for use thereof |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2592370C9 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US10080760B2 (en) * | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
SG192114A1 (en) * | 2011-01-26 | 2013-08-30 | Allergan Inc | Androgen composition for treating an opthalmic condition |
-
2014
- 2014-04-24 RU RU2014116566/15A patent/RU2592370C9/en active IP Right Revival
Also Published As
Publication number | Publication date |
---|---|
RU2592370C2 (en) | 2016-07-20 |
RU2592370C9 (en) | 2016-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084932A1 (en) | OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY | |
RU2009148278A (en) | The use of estriol in a low dose | |
GEP20227407B (en) | Contraceptive composition with reduced cardiovascular effects | |
EA200900491A1 (en) | USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
AR079925A1 (en) | GEL-BASED COMPOSITIONS AND METHODS TO MANUFACTURE THEM | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
PH12017502379A1 (en) | Drospirenone-based contraceptive for a female patient affected with excess weight | |
GEP20227396B (en) | Compounds and their uses for alleviating menopause-associated symptoms | |
RU2011103136A (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF FINE-GROWED PROGESTERON AND ITS APPLICATIONS | |
NZ606768A (en) | Pharmaceutical compositions and methods of treatment | |
JP2018527305A5 (en) | ||
PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
GEP20227395B (en) | Compounds and their uses for alleviating menopause-associated symptoms | |
GB201200858D0 (en) | Prebiotic powder composition and uses thereof | |
NZ751972A (en) | Treatment of prurigo nodularis | |
MX2023005875A (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dio xolo[4,5-f]indol-7-yl)pyrrole-2,5-dione. | |
MX2015006370A (en) | Herbal supplements and methods of use thereof. | |
RU2014116566A (en) | MEANS ON THE BASIS OF DEHYDROEPIANDROSTERONE, METHOD OF ITS APPLICATION | |
PE20090805A1 (en) | COMBINATION OF DROSPIRENONE AND 17ß-ESTRADIOL AS AN ORAL CONTRACEPTIVE | |
MX2013012038A (en) | Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin. | |
MX346467B (en) | A composition comprising at least one alginate for use in treatment and/or prevention of overweight. | |
MX2019013851A (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine. | |
WO2017100378A3 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
MX2016011801A (en) | Low-dose estradiol cream. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Reissue of patent specification | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180425 |
|
NF4A | Reinstatement of patent |
Effective date: 20190218 |